STAT3 and small cell lung carcinoma: Mechanistic studies reveal that DLL3-high SCLC tumors exhibit STAT3-driven PD-L1 upregulation, creating an immunosuppressive niche resistant to immune checkpoint inhibitors (ICIs) (56).